Stock DNA
Pharmaceuticals & Biotechnology
SEK 86 Million ()
NA (Loss Making)
NA
0.00%
-0.93
-591.46%
74.31
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Dec 2023)
Net Profit:
-1 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-32.17%
0%
-32.17%
6 Months
-40.46%
0%
-40.46%
1 Year
-52.73%
0%
-52.73%
2 Years
-21.21%
0%
-21.21%
3 Years
-41.56%
0%
-41.56%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Pila Pharma AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
7.30%
EBIT Growth (5y)
-23.12%
EBIT to Interest (avg)
-8.42
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.93
Sales to Capital Employed (avg)
0.38
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
85.69
EV to EBIT
-15.37
EV to EBITDA
-18.48
EV to Capital Employed
98.24
EV to Sales
67.15
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-639.30%
ROE (Latest)
-591.46%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'23 - QoQ
Dec'23
Sep'23
Change(%)
Net Sales
0.40
0.00
Operating Profit (PBDIT) excl Other Income
-1.00
-1.20
16.67%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1.30
-1.50
13.33%
Operating Profit Margin (Excl OI)
-3,480.90%
0.00%
-348.09%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2023 is 0.00% vs -100.00% in Sep 2023
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2023 is 13.33% vs 51.61% in Sep 2023
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
0.80
1.50
-46.67%
Operating Profit (PBDIT) excl Other Income
-7.00
-5.30
-32.08%
Interest
0.10
0.00
Exceptional Items
-3.10
-3.50
11.43%
Consolidate Net Profit
-11.20
-9.90
-13.13%
Operating Profit Margin (Excl OI)
-10,484.30%
-4,369.90%
-611.44%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -46.67% vs -21.05% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -13.13% vs 63.06% in Dec 2023
About Pila Pharma AB 
Pila Pharma AB
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






